{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:15Z","timestamp":1790803695525,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","award":["260\/01"],"award-info":[{"award-number":["260\/01"]}],"id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.chest.2024.03.033","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T03:23:26Z","timestamp":1711077806000},"page":"433-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor\/Tezacaftor\/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-3131","authenticated-orcid":false,"given":"Andrea","family":"Gramegna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Premuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-9301","authenticated-orcid":false,"given":"Francesca","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Retucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vespro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Andrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Carraffiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8248-7785","authenticated-orcid":false,"given":"Francesco","family":"Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10059","key":"10.1016\/j.chest.2024.03.033_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"10212","key":"10.1016\/j.chest.2024.03.033_bib2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.chest.2024.03.033_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2024.03.033_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2021.01.001","article-title":"Elexacaftor-tezacaftor-ivacaftor: the new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation","volume":"57","author":"Gramegna","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.chest.2024.03.033_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.chest.2024.03.033_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chest.2024.03.033_bib7","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.03.033_bib8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jpeds.2004.02.038","article-title":"High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests","volume":"145","author":"Brody","year":"2004","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.chest.2024.03.033_bib10","series-title":"Quantile regression","author":"Koenker","year":"2005"},{"issue":"6","key":"10.1016\/j.chest.2024.03.033_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2307\/1913398","article-title":"Tests of linear hypotheses and l\u20191 estimation","volume":"50","author":"Koenker","year":"1982","journal-title":"Econometrica"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcf.2021.03.016","article-title":"Peripheral lung effect of elexacaftor\/tezacaftor\/ivacaftor in adult cystic fibrosis","volume":"21","author":"Stylemans","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.chest.2024.03.033_bib13","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.7829","article-title":"Investigating the relationships among lung function variables in chronic obstructive pulmonary disease in men","volume":"7","author":"Chuang","year":"2019","journal-title":"PeerJ"},{"issue":"246","key":"10.1016\/j.chest.2024.03.033_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/adc.46.246.144","article-title":"Pulmonary function and response to exercise in cystic fibrosis","volume":"46","author":"Godfrey","year":"1971","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1465-9921-7-138","article-title":"Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis","volume":"7","author":"Kraemer","year":"2006","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/resp.12906","article-title":"Clinical value of pulmonary hyperinflation as a treatment outcome in cystic fibrosis","volume":"22","author":"Stevens","year":"2017","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/resp.12885","article-title":"Relationship between pulmonary hyperinflation and dyspnea severity during acute exacerbations of cystic fibrosis","volume":"22","author":"Nicholson","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.chest.2024.03.033_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.rmed.2018.10.031","article-title":"A comprehensive approach to lung function in bronchiectasis","volume":"145","author":"Radovanovic","year":"2018","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2024.03.033_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","volume":"65","author":"Turcios","year":"2020","journal-title":"Respir Care"},{"issue":"9","key":"10.1016\/j.chest.2024.03.033_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest CT scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - The RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2024.03.033_bib21","doi-asserted-by":"crossref","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2024.03.033_bib22","first-page":"120","article-title":"Correlation between hyperinflation defined as an elevated RV\/TLC ratio and body composition and cytokine profile in patients with chronic obstructive pulmonary disease","volume":"83","author":"Rubinsztajn","year":"2015","journal-title":"Pneumonol Alergol Pol"},{"issue":"3","key":"10.1016\/j.chest.2024.03.033_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.23736\/S0026-4806.22.07974-5","article-title":"Mechanical ventilation and COPD: from pathophysiology to ventilatory management","volume":"113","author":"Scaramuzzo","year":"2022","journal-title":"Minerva Med"},{"issue":"3","key":"10.1016\/j.chest.2024.03.033_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1183\/09031936.00120609","article-title":"Therapeutic implications of the pathophysiology of COPD","volume":"35","author":"Macklem","year":"2010","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2024.03.033_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/resp.13688","article-title":"Reduced lung elastic recoil and fixed airflow obstruction in asthma","volume":"25","author":"Tonga","year":"2020","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.chest.2024.03.033_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ppul.1950150103","article-title":"Lung recoil and the determination of airflow limitation in cystic fibrosis and asthma","volume":"15","author":"Zapletal","year":"1993","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.chest.2024.03.033_bib27","first-page":"190","article-title":"Lung elastic recoil in cystic fibrosis","volume":"109","author":"Mansell","year":"1974","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.chest.2024.03.033_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1034\/j.1399-3003.2000.15d18.x","article-title":"Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs","volume":"15","author":"Tiddens","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.03.033_bib29","doi-asserted-by":"crossref","first-page":"2101344","DOI":"10.1183\/13993003.01344-2021","article-title":"Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis","author":"Campredon","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.03.033_bib30","doi-asserted-by":"crossref","first-page":"110421","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur J Radiol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224004045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224004045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:56:15Z","timestamp":1777380975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224004045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0012369224004045"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.03.033","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor\/Tezacaftor\/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}